Testing garsorasib for advanced KRAS G12C lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an oral targeted drug called Garsorasib for people with advanced lung cancer that has a specific KRAS G12C mutation and has not received previous treatment for advanced disease. The goal is to see if it can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced (Stage IIIB or IV) non-small cell lung cancer that has not been treated yet.
- Your tumor has a specific gene change called KRAS G12C, and you have a PD-L1 test result.
- You are generally able to care for yourself (ECOG score 0 or 1).
- Your blood counts, kidney, and liver function must be within a healthy range.
- You do not have uncontrolled brain metastases, serious heart disease, or other active cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GFH375, either alone or combined with other treatments, for advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if this targeted approach can slow or shrink your cancer better than standard treatments.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This trial tests a new approach for people with a specific type of lung cancer (KRAS G12C) that is still confined to the chest and can be surgically removed. It combines a targeted pill (garsorasib) followed by immunotherapy + chemotherapy before surgery, to see if this can shrink the tumor and improve outcomes.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This trial tests a new drug called HRS-7058 for patients with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and has stopped responding to standard treatments. The drug is designed to target and block this mutation.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new Local Advanced or Metastatic NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.